- Missed consensus for Q1 EPS and revs. Sales declined 8% yr/yr on anorganic basis. Comparisons were impacted by lapping COVID-19 stockpiling trends from the year-ago period, as well as consumer tissue category softness and commodity inflation; co also experienced temporary supply chain disruptions in the southern US. Lowered its outlook for FY21 EPS and sales growth, reflecting significantly higher input cost inflation and lower sales volumes.
** charts after earnings **
Kimberly-Clark misses by $0.14, misses on revs; slightly lowers FY21 EPS, revs outlook
- Reports Q1 (Mar) earnings of $1.80 per share, excluding non-recurring items, $0.14 worse than the S&P Capital IQ Consensus of $1.94; revenues fell 5.3% year/year to $4.74 bln vs the$4.97 bln S&P Capital IQ Consensus.
- Co issues guidance for FY21, sees EPS of $7.30-7.55, excluding non-recurring items, (from$7.75-8.00) vs. $7.77 S&P Capital IQ Consensus; sees FY21 sales growth of +3-5% (prior +4-6%) which equates to about $19.67-20.06 bln vs. $19.99 bln S&P Capital IQ Consensus.
No comments:
Post a Comment